RxDoctor Payments Data

Keerthana Kumar, MD

Public Health & General Preventive Medicine · Poughkeepsie, NYNPI 1932737079

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,470 of the $8,026 with a category attached, or 68.2%. 10 manufacturers reported payments, led by Pfizer at 33.2% of the total. 2025 is the largest year on record at $3,867, 2.3 times the $1,653 reported in 2023.

$8,026in general payments, 2019–2025

Across 140 payments — averaging $57.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3K
  • AbbVie$2K
  • Ipsen Innovation$1K
  • Teva Pharmaceuticals USA, Inc.$981
  • Lundbeck LLC$629
  • E.r. Squibb & Sons, L.L.C.$150
  • plus $282 from 4 others

What the payments were for

  • Consulting fees$1,52519%
  • Travel & lodging$1,02613%
  • Food & beverage$5,47068%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,026 in reported general payments places this provider in the 85th percentile of 30 public health & general preventive medicine providers in New York.

See all public health & general preventive medicine providers in New York

Medicare billing

Part B allowed, 2024
$67,331
Medicare patients
76
Services billed
4,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate80$125,071
UbrelvyUbrogepant63$95,881
QuliptaAtogepant54$65,904
Emgality PenGalcanezumab-Gnlm15$10,300
Dihydroergotamine Mesylate11$6,153
Tizanidine Hcl33$896
Gabapentin54$622
Naratriptan Hcl15$422
RizatriptanRizatriptan Benzoate24$313
Memantine Hcl16$297
Donepezil Hcl37$254
Nabumetone26$174
Meclizine Hcl23$158
Ondansetron OdtOndansetron13$111
Prednisone20$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,999$161,785117 claims
PfizerNurtec Odt$2,664$125,07180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 public health & general preventive medicine providers in New York.

Other public health & general preventive medicine in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →